Predictive role of γ-glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma

被引：0
|
作者：
Yudai Ishiyama
Tsunenori Kondo
Hidekazu Tachibana
Hiroki Ishihara
Hironori Fukuda
Kazuhiko Yoshida
Toshio Takagi
Junpei Iizuka
Kazunari Tanabe
机构：
[1] Tokyo Women’s Medical University Medical Center East,Department of Urology
[2] Tokyo Women’s Medical University,Department of Urology
来源：
International Journal of Clinical Oncology | 2021年 / 26卷
关键词：
Metastatic kidney cancer; Biomarkers; Immunotherapy; Immune-checkpoint inhibitor; Prognosticator;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：552 / 561
页数：9
相关论文
共 50 条
  • [21] Safety and efficacy of nivolumab therapy in patients with metastatic renal cell carcinoma and impaired kidney function
    Sengul, N.
    Gulturk, I.
    Yilmaz, M.
    Celik, E.
    Paksoy, N.
    Yekeduz, E.
    Urun, Y.
    Basaran, M.
    Ozguroglu, M.
    ACTAS UROLOGICAS ESPANOLAS, 2024, 48 (04): : 273 - 280
  • [22] Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma
    Kobari, Yuki
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Kondo, Tsunenori
    Ishida, Hideki
    Tanabe, Kazunari
    Takagi, Toshio
    IN VIVO, 2021, 35 (06): : 3585 - 3589
  • [23] Optimal sequence strategy with nivolumab and targeted therapy in patients with metastatic renal cell carcinoma (mRCC)
    Logeart, Juliette
    Simonaggio, Audrey
    Elaidi, Reza Thierry
    Hans, Sophie
    Thibault, Constance
    Oudard, Stephane
    Vano, Yann-Alexandre
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [24] Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
    Garmezy, Benjamin
    Zhang, Tian
    Laccetti, Andrew Leonard
    Economides, Minas P.
    Shah, Amishi Yogesh
    Tannir, Nizar M.
    Jonasch, Eric
    Msaouel, Pavlos
    Zurita, Amado J.
    Corn, Paul Gettys
    Venkatesan, Aradhana M.
    Brown, Landon Carter
    Kao, Chester
    Kinsey, Emily Noelle
    Harrison, Michael Roger
    Armstrong, Andrew J.
    George, Daniel J.
    Campbell, Matthew T.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma
    Segawa, Takuya
    Motoshima, Takanobu
    Yatsuda, Junji
    Kurahashi, Ryoma
    Fukushima, Yumi
    Murakami, Yoji
    Yamaguchi, Takahiro
    Sugiyama, Yutaka
    Yoshida, Ryoji
    Nakayama, Hideki
    Kamba, Tomomi
    IJU CASE REPORTS, 2023, 6 (02) : 147 - 149
  • [26] NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A PREDICTIVE BIOMARKER FOR RESPONSE TO NIVOLUMAB IN ASIAN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Bando, Yukari
    Sakamoto, Mariko
    Okamura, Yasuyoshi
    Suzuki, Kotaro
    Hara, Takuto
    Terakawa, Tomoaki
    Furukawa, Junya
    Harada, Kenichi
    Hinata, Nobuyuki
    Nakano, Yuzo
    Fujisawa, Masato
    JOURNAL OF UROLOGY, 2019, 201 (04): : E344 - E345
  • [27] Renal allograft rejection after treatment with nivolumab in patients with metastatic renal cell carcinoma
    Ishikawa, Gaku
    Sugiyama, Takayuki
    Ito, Toshiki
    Otsuka, Atsushi
    Miyake, Hideaki
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2021, 10 (02) : 116 - 118
  • [28] The role of targeted therapy in metastatic renal cell carcinoma
    Unnithan, Jaya
    Rini, Brian I.
    THESCIENTIFICWORLDJOURNAL, 2007, 7 : 800 - 807
  • [29] Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma
    Hiroki Ishihara
    Hidekazu Tachibana
    Toshio Takagi
    Tsunenori Kondo
    Hironori Fukuda
    Kazuhiko Yoshida
    Junpei Iizuka
    Hirohito Kobayashi
    Masayoshi Okumi
    Hideki Ishida
    Kazunari Tanabe
    Targeted Oncology, 2019, 14 : 453 - 463
  • [30] Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma
    Ishihara, Hiroki
    Tachibana, Hidekazu
    Takagi, Toshio
    Kondo, Tsunenori
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Kobayashi, Hirohito
    Okumi, Masayoshi
    Ishida, Hideki
    Tanabe, Kazunari
    TARGETED ONCOLOGY, 2019, 14 (04) : 453 - 463
12345